nContact's ablation technology succeeds in study
This article was originally published in Clinica
Ablation of heart tissue using technology developed by nContact Surgical (Raleigh, North Carolina) can successfully treat persistent atrial fibrillation (AF), a small-scale trial has suggested. In the study, 43 patients underwent a closed chest convergent procedure, which combines epicardial and endocardial ablation via a minimally-invasive, closed chest approach. Diagnostic endocardial mapping technology was used during the three-hour procedure to ensure complete bi-atrial ablation and to confirm procedural endpoints. The patients had suffered AF an average of eight years and had enlarged left atria; this is considered one of the more difficult patient populations to treat. After three months, 81% of the patients were free of arrhythmia recurrence. The data were presented at the annual meeting of the Heart Rhythm Society, held in Denver, Colorado, on 12-15 May.